

In Figure 3(C), in the last line, delete "L.W." and substitute therefor -- L... --.

In the claims

Please cancel claims 1-61 without prejudice or disclaimer and enter the following new claims:

62. (New) A method of delaying recurrence of a GD2-associated tumor in an individual, comprising administering to the individual an effective amount of an antibody comprising the light and heavy chain variable region sequences contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

63. (New) The method of claim 62, wherein the GD2-associated tumor is melanoma.

64. (New) The method of claim 62, wherein the GD2-associated tumor is neuroblastoma.

65. (New) The method of claim 62, wherein the GD2-associated tumor is glioma.

66. (New) The method of claim 62, wherein the GD2-associated tumor is sarcoma.

67. (New) The method of claim 62, wherein the GD2-associated tumor is small cell lung cancer.

68. (New) The method of claim 62, wherein said antibody is administered with an adjuvant.

69. (New) The method of claim 68, wherein the adjuvant is aluminum hydroxide.

9. ~~70~~ (New) The method of claim ~~62~~, wherein said antibody is administered in an amount of about 1 mg to about 4 mg.

10. ~~71~~ (New) The method of claim ~~62~~, wherein said antibody is administered in an amount of about 1 mg.

11. ~~72~~ (New) The method of claim ~~62~~, wherein said antibody is administered in an amount of about 2 mg.

12. ~~73~~ (New) The method of claim ~~62~~, wherein said antibody is administered at weekly intervals.

13. ~~74~~ (New) The method of claim ~~62~~, wherein said antibody is administered at bi-weekly intervals.

14. ~~75~~ (New) The method of claim ~~62~~, wherein said antibody is heat-treated prior to administration.

15. ~~76~~ (New) A method of delaying development of a GD2-associated tumor in an individual, comprising administering to the individual an effective amount of an antibody comprising the light and heavy chain variable region sequences contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

16. ~~77~~ (New) The method of claim ~~76~~, wherein the GD2-associated tumor is melanoma.

17. ~~78~~ (New) The method of claim ~~76~~, wherein the GD2-associated tumor is neuroblastoma.

156

Q

A4
CONT'D.

665110-6656260

118¹⁵ 79. (New) The method of claim 76, wherein the GD2-associated tumor is glioma.

119¹⁵ 80. (New) The method of claim 76, wherein the GD2-associated tumor is sarcoma.

120¹⁵ 81. (New) The method of claim 76, wherein the GD2-associated tumor is small cell lung cancer.

121¹⁵ 82. (New) The method of claim 76, wherein said antibody is administered with an adjuvant.

122²¹ 83. (New) The method of claim 82, wherein the adjuvant is aluminum hydroxide.

123¹⁵ 84. (New) The method of claim 76, wherein said antibody is administered in an amount of about 1 mg to about 4 mg.

124¹⁵ 85. (New) The method of claim 76, wherein said antibody is administered in an amount of about 1 mg.

125¹⁵ 86. (New) The method of claim 76, wherein said antibody is administered in an amount of about 2 mg.

126¹⁵ 87. (New) The method of claim 76, wherein said antibody is administered at weekly intervals.

127¹⁵ 88. (New) The method of claim 76, wherein said antibody is administered at bi-weekly intervals.

A4
cont'd.

005410-8856260